Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Quarterly report · Q3

4886.TEDINET S100Q4CE
Period2022-04-01 → 2022-12-31
Filed2023-02-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥47.3bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥56.6bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥44.2bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥5.0bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥4.7bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥5.2bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥4.9bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.8bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥5.4bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥5.8bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥4.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.3bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥4.1bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥4.2bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥4.1bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥90.8bnat 2022-12-31Cons.Assets
Total assets¥83.3bnat 2022-03-31Cons.Assets
Total assets¥87.5bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥36.7bnat 2022-12-31Cons.Liabilities
Total liabilities¥34.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥54.1bnat 2022-12-31Cons.Net assets
Net assets / equity¥48.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥48.4bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥18.5bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥12.1bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥148.192022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥64.972022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥151.222021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥143.762021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥242.12021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio59.6%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio58.7%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio55.3%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥196m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥155m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥41m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31−¥26m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥41m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥41m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥767m
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥417m
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥41.9bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥41.9bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥5.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥47.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥47.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥41m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥5.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-12-31¥158m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-12-31¥116m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-12-31¥41m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-12-31−¥42m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥41m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥41m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥495m
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥4.4bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥4.4bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥329m
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥39.7bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥39.7bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥4.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥44.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥44.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥41m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥5.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 340
ItemContextValueUnit
Other clCurrentQuarterInstant8229000000JPY
Current liabilitiesPrior1YearInstant16011000000JPY
Current liabilitiesCurrentQuarterInstant20809000000JPY
Long term loans payablePrior1YearInstant12323000000JPY
Long term loans payableCurrentQuarterInstant9629000000JPY
Net defined benefit liabilityPrior1YearInstant5730000000JPY
Net defined benefit liabilityCurrentQuarterInstant5943000000JPY
Other nclPrior1YearInstant338000000JPY
Other nclCurrentQuarterInstant332000000JPY
Noncurrent liabilitiesPrior1YearInstant18393000000JPY
Noncurrent liabilitiesCurrentQuarterInstant15904000000JPY
LiabilitiesPrior1YearInstant34404000000JPY
LiabilitiesCurrentQuarterInstant36713000000JPY
Capital stockPrior1YearInstant1197000000JPY
Capital stockCurrentQuarterInstant1197000000JPY
Capital surplusPrior1YearInstant1867000000JPY
Capital surplusCurrentQuarterInstant1847000000JPY
Retained earningsPrior1YearInstant45833000000JPY
Retained earningsCurrentQuarterInstant49564000000JPY
Treasury stockPrior1YearInstant-3479000000JPY
Treasury stockCurrentQuarterInstant-3358000000JPY
Shareholders equityPrior1YearInstant45419000000JPY
Shareholders equityCurrentQuarterInstant49252000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant3231000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant4079000000JPY
Foreign currency translation adjustmentPrior1YearInstant164000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant650000000JPY
Remeasurements of defined benefit plansPrior1YearInstant77000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant97000000JPY
Valuation and translation adjustmentsPrior1YearInstant3473000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant4828000000JPY
Net assetsPrior1YearInstant48892000000JPY
Net assetsCurrentQuarterInstant54080000000JPY
Liabilities and net assetsPrior1YearInstant83297000000JPY
Liabilities and net assetsCurrentQuarterInstant90794000000JPY
Net salesPrior1YTDDuration44179000000JPY
Net salesCurrentYTDDuration47259000000JPY
Cost of salesPrior1YTDDuration23485000000JPY
Cost of salesCurrentYTDDuration24893000000JPY
Gross profitPrior1YTDDuration20694000000JPY
Gross profitCurrentYTDDuration22366000000JPY
Selling general and administrative expensesPrior1YTDDuration16017000000JPY
Selling general and administrative expensesCurrentYTDDuration17324000000JPY
Operating incomePrior1YTDDuration4677000000JPY
Operating incomeCurrentYTDDuration5041000000JPY
Interest income noiPrior1YTDDuration0JPY
Interest income noiCurrentYTDDuration0JPY
Dividends income noiPrior1YTDDuration251000000JPY
Dividends income noiCurrentYTDDuration331000000JPY
Other noiPrior1YTDDuration115000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass